Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Aurobindo Pharma Limited (AUROPHARMA.NS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 570.45 M | 43.74 M | 1.8 B | 5.34 B | 2.87 B |
| 2022 | 528.96 M | 105.39 M | 1.54 B | 4.72 B | 2.55 B |
| 2021 | 475.17 M | -104,639,161 | 1.11 B | 4.02 B | 2.15 B |
| 2020 | 414.89 M | 20.88 M | 1.41 B | 4.01 B | 2.35 B |
| 2019 | 511.05 M | 418.95 M | 1.43 B | 3.43 B | 1.94 B |